Literature DB >> 20070183

Delayed release film coating applications on oral solid dosage forms of proton pump inhibitors: case studies.

Shahrzad Missaghi1, Cara Young, Kurt Fegely, Ali R Rajabi-Siahboomi.   

Abstract

BACKGROUND: Formulation of proton pump inhibitors (PPIs) into oral solid dosage forms is challenging because the drug molecules are acid-labile. The aim of this study is to evaluate different formulation strategies (monolithic and multiparticulates) for three PPI drugs, that is, rabeprazole sodium, lansoprazole, and esomeprazole magnesium, using delayed release film coating applications.
METHOD: The core tablets of rabeprazole sodium were prepared using organic wet granulation method. Multiparticulates of lansoprazole and esomeprazole magnesium were prepared through drug layering of sugar spheres, using powder layering and suspension layering methods, respectively. Tablets and drug-layered multiparticulates were seal-coated, followed by delayed release film coating application, using Acryl-EZE(R), aqueous acrylic enteric system. Multiparticulates were then filled into capsules. The final dosage forms were evaluated for physical properties, as well as in vitro dissolution testing in both compendial acid phase, 0.1N HCl (pH 1.2), and intermediate pH, acetate buffer (pH 4.5), followed by phosphate buffer, pH 6.8. The stability of the delayed release dosage forms was evaluated upon storage in accelerated conditions [40 degrees C/75% relative humidity] for 3 months.
RESULTS: All dosage forms demonstrated excellent enteric protection in the acid phase, followed by rapid release in their respective buffer media. Moreover, the delayed release dosage forms remained stable under accelerated stability conditions for 3 months.
CONCLUSIONS: Results showed that Acryl-EZE enteric coating systems provide excellent performance in both media (0.1N HCl and acetate buffer pH 4.5) for monolithic and multiparticulate dosage forms.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20070183     DOI: 10.3109/03639040903468811

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  9 in total

1.  Influence of some formulation variables on the optimization of pH-dependent, colon-targeted, sustained-release mesalamine microspheres.

Authors:  Ahmed Abd El-Bary; Ahmed A Aboelwafa; Ibrahim M Al Sharabi
Journal:  AAPS PharmSciTech       Date:  2011-12-01       Impact factor: 3.246

2.  Evaluation of coating properties of enteric-coated tablets using terahertz pulsed imaging.

Authors:  Masahiro Niwa; Yasuhiro Hiraishi; Katsuhide Terada
Journal:  Pharm Res       Date:  2014-02-27       Impact factor: 4.200

3.  In Vitro Evaluation of Nasogastric Tube Delivery Performance of Esomeprazole Magnesium Delayed-Release Capsules.

Authors:  Alicia Hoover; Dajun Sun; Hong Wen; Wenlei Jiang; Minglei Cui; Xiaojian Jiang; David Keire; Changning Guo
Journal:  J Pharm Sci       Date:  2017-04-15       Impact factor: 3.534

4.  Influences of sodium carbonate on physicochemical properties of lansoprazole in designed multiple coating pellets.

Authors:  Wei He; Min Yang; Jun Hong Fan; Cai Xia Feng; Su Juan Zhang; Jin Xu Wang; Pei Pei Guan; Wei Wu
Journal:  AAPS PharmSciTech       Date:  2010-08-18       Impact factor: 3.246

5.  Effect of Elevated pH on the Commercial Enteric-Coated Omeprazole Pellets Resistance: Patent Review and Multisource Generics Comparison.

Authors:  Valentyn Mohylyuk; Anna Yerkhova; Marina Katynska; Vitaliy Sirko; Kavil Patel
Journal:  AAPS PharmSciTech       Date:  2021-06-22       Impact factor: 3.246

6.  Eudragit L/HPMCAS blend enteric-coated lansoprazole pellets: enhanced drug stability and oral bioavailability.

Authors:  Yu Fang; Guozheng Wang; Rong Zhang; Zhihua Liu; Zhenghua Liu; Xiaohui Wu; Deying Cao
Journal:  AAPS PharmSciTech       Date:  2014-03-05       Impact factor: 3.246

7.  Pharmacokinetics and Pharmacodynamics of Esomeprazole/Sodium Bicarbonate Immediate-Release Capsules in Healthy Chinese Volunteers: A Cross-Over, Randomized Controlled Trial.

Authors:  Shan Jing; Yue Zhu; Wenfang Liu; Kexu Yang; Lili Hu; Dan Deng; Chunyan Lu; Yang Lin
Journal:  Adv Ther       Date:  2021-02-11       Impact factor: 3.845

8.  The safety, pharmacodynamics, and pharmacokinetics of immediate-release formulation containing esomeprazole 20 mg/sodium bicarbonate 800 mg in healthy adult male.

Authors:  Dasohm Kim; Min Soo Park; Byung Won Yoo; Taegon Hong; Shin Jung Park; Choon Ok Kim
Journal:  Drug Des Devel Ther       Date:  2019-09-03       Impact factor: 4.162

9.  In Vitro Evaluation of Enteric-Coated HPMC Capsules-Effect of Formulation Factors on Product Performance.

Authors:  Maoqi Fu; Johannes Andreas Blechar; Andreas Sauer; Jozef Al-Gousous; Peter Langguth
Journal:  Pharmaceutics       Date:  2020-07-23       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.